Celldex TherapeuticsCLDX
CLDX
About: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Employees: 160
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
46% more call options, than puts
Call options by funds: $24.9M | Put options by funds: $17.1M
28% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 50
2.66% more ownership
Funds ownership: 108.41% [Q3] → 111.07% (+2.66%) [Q4]
6% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 36
1% less funds holding
Funds holding: 176 [Q3] → 174 (-2) [Q4]
24% less capital invested
Capital invested by funds: $2.44B [Q3] → $1.86B (-$581M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$44
96%
upside
Avg. target
$64
183%
upside
High target
$80
256%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
UBS Trung Huynh 57% 1-year accuracy 4 / 7 met price target | 96%upside $44 | Buy Initiated | 13 Feb 2025 |
Cantor Fitzgerald Kristen Kluska 43% 1-year accuracy 46 / 107 met price target | 198%upside $67 | Overweight Reiterated | 29 Jan 2025 |
HC Wainwright & Co. Joseph Pantginis 23% 1-year accuracy 93 / 411 met price target | 256%upside $80 | Buy Reiterated | 20 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 months ago
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is actively enrolling patients. AD is one of the most common chronic inflammatory skin diseases, with a lifetime prevalence of up to 20% of the US population and a substantial impact on quality of life1. Mast cells are strongly implicated in all facets of AD pathophysiology and the fundamental processes that characterize AD, including epithelial barrier dysfunction, immune cell recruitment, neuroinflammation2 and multiple other mast cell-associated factors that correlate with disease severity. Activated mast cells are also found in increased numbers in lesional biopsies. Barzolvolimab is a humanized monoclonal antibody that specifically binds and blocks the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell.
Neutral
GlobeNewsWire
3 months ago
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation.
Neutral
GlobeNewsWire
3 months ago
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Negative
Zacks Investment Research
3 months ago
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
HAMPTON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Positive
Seeking Alpha
3 months ago
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market
Celldex's primary revenue driver is Barzolvolimab, now in Phase 3 for CSU, targeting unmet needs in inflammatory diseases. Barzolvolimab has shown strong Phase 2 efficacy for CSU, though safety concerns may affect patient adherence. Celldex's solid cash position and long runway reduce dilution risks, supporting the continued development of its pipeline.
Neutral
GlobeNewsWire
3 months ago
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.
Neutral
GlobeNewsWire
3 months ago
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
HAMPTON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD)—will be presented in a late breaking oral presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) Annual Scientific Meeting being held in Boston October 24-28, 2024.
Neutral
Zacks Investment Research
4 months ago
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Neutral
GlobeNewsWire
4 months ago
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
- 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across omalizumab-experienced/refractory/naïve disease - - Well tolerated through 52 weeks - - Enrollment to Global Phase 3 CSU trials underway - - Company to host webcast today at 12:00 pm ET/6:00 pm CEST -
Charts implemented using Lightweight Charts™